Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H30O2 |
Molecular Weight | 290.4403 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])C[C@@H](O)CC[C@]34C
InChI
InChIKey=QGXBDMJGAMFCBF-LUJOEAJASA-N
InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12-16,20H,3-11H2,1-2H3/t12-,13-,14-,15-,16-,18-,19-/m0/s1
Molecular Formula | C19H30O2 |
Molecular Weight | 290.4403 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22037250Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7726568 | https://www.ncbi.nlm.nih.gov/pubmed/12054855 | https://www.ncbi.nlm.nih.gov/pubmed/15650074 | https://www.ncbi.nlm.nih.gov/pubmed/17017935
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22037250
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7726568 | https://www.ncbi.nlm.nih.gov/pubmed/12054855 | https://www.ncbi.nlm.nih.gov/pubmed/15650074 | https://www.ncbi.nlm.nih.gov/pubmed/17017935
The 17-ketosteroid epiandrosterone is a metabolite of testosterone precursor dehydroepiandrosterone (DHEA).
Epiandrosterone have been considered to be merely inactive end product of DHEA, but may in fact be physiological effectors in their own right. It is formed in peripheral tissues, from which it is released into the circulation and is ultimately excreted in the urine. Epiandrosterone is only a weak androgen, but it is widely recognized to inhibit the pentose phosphate pathway and to decrease intracellular NADPH levels. Epiandrosterone may act as a L-type Ca2+ channel antagonist. Epiandrosterone mainly transformed into 17beta-hydroxylated derivatives, 7- or 16alpha-hydroxylated metabolites under NAD(P)H conditions, and 5alpha-androstane-3,17-dione under NAD(P)+ conditions. Epiandrosterone is used as an anabolic agent (dietary supplement, a precursor to dihydrotestosterone) to increase strength, muscle hardness and also improves libido.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22508085
Curator's Comment: Androsterone injections increased brain levels of epiandrosterone in rats. No human data available.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12054855 |
|||
Target ID: CHEMBL5347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7726568 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). | 2001 Jun |
|
Use of bioconversion for the preparation of [4-14C]-labeled 7 alpha- and 7 beta-hydroxylated derivatives of dehydroepiandrosterone and epiandrosterone. | 2002 Dec |
|
Epiandrosterone, a metabolite of testosterone precursor, blocks L-type calcium channels of ventricular myocytes and inhibits myocardial contractility. | 2002 Jun |
|
Pentose phosphate pathway coordinates multiple redox-controlled relaxing mechanisms in bovine coronary arteries. | 2003 Dec |
|
A facile and high yielding synthesis of 2,2,3,4,4-d5-androsterone-beta-D-glucuronide--an internal standard in dope. | 2003 Jan |
|
Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. | 2003 Jan |
|
7-Hydroxylated epiandrosterone (7-OH-EPIA) reduces ischaemia-induced neuronal damage both in vivo and in vitro. | 2003 Jul |
|
The human cytochrome P4507B1: catalytic activity studies. | 2004 Dec |
|
In vitro metabolism of dehydroepiandrosterone and testosterone by canine hair follicle cells. | 2004 Feb |
|
Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid. | 2004 Mar |
|
Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Müllerian inhibiting substance. | 2004 Oct |
|
Neurosteroids: metabolism in human intestine microsomes. | 2005 Apr |
|
Human liver S9 fractions: metabolism of dehydroepiandrosterone, epiandrosterone, and related 7-hydroxylated derivatives. | 2005 Apr |
|
Glucuronidation of steroidal alcohols using iodosugar and imidate donors. | 2005 Apr 21 |
|
Role of pentose phosphate pathway-derived NADPH in hypoxic pulmonary vasoconstriction. | 2006 |
|
Steroid hormone related male biased parasitism in chamois, Rupicapra rupicapra rupicapra. | 2006 Jun 15 |
|
An open label, dose response study to determine the effect of a dietary supplement on dihydrotestosterone, testosterone and estradiol levels in healthy males. | 2008 Aug 12 |
|
Isolation and identification of diglucuronides of some endogenous steroids in dogs. | 2008 Feb |
|
7beta-Hydroxy-epiandrosterone-mediated regulation of the prostaglandin synthesis pathway in human peripheral blood monocytes. | 2008 Oct |
|
Diagnosis of diseases of steroid hormone production, metabolism and action. | 2009 |
|
Anabolic utilization of steroid hormones in Helicobacter pylori. | 2009 Aug |
|
Preferential utilization of NADPH as the endogenous electron donor for NAD(P)H:quinone oxidoreductase 1 (NQO1) in intact pulmonary arterial endothelial cells. | 2009 Jan 1 |
|
A review of the current treatment methods for posthaemorrhagic hydrocephalus of infants. | 2009 Jan 30 |
|
Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants. | 2009 Jun 2 |
|
Epimerase activity of the human 11beta-hydroxysteroid dehydrogenase type 1 on 7-hydroxylated C19-steroids. | 2009 Mar |
|
Effects of valproate and carbamazepine monotherapy on neuroactive steroids, their precursors and metabolites in adult men with epilepsy. | 2010 Oct |
Sample Use Guides
Epiandrosterone is used as an anabolic agent (dietary supplement). Recommended dosing is 300-400 mg for a 6-8 week cycle.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12933338
Epiandrosterone (1-500 uM) elicited dose-dependent relaxation in chemically contracted endothelium-removed bovine coronary arteries
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:19:53 UTC 2023
by
admin
on
Fri Dec 15 15:19:53 UTC 2023
|
Record UNII |
8TR252Z538
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
2229-3
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
||
|
DSLD |
2986 (Number of products:14)
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
||
|
NCI_THESAURUS |
C243
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Epiandrosterone
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
441302
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | |||
|
207-563-3
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | |||
|
C61747
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | |||
|
541975
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | |||
|
481-29-8
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | |||
|
DTXSID20289698
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | |||
|
m4934
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | Merck Index | ||
|
93996
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | |||
|
EPIANDROSTERONE
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY | |||
|
8TR252Z538
Created by
admin on Fri Dec 15 15:19:53 UTC 2023 , Edited by admin on Fri Dec 15 15:19:53 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|